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Myrrh has been used as an antibacterial and anti-inﬂammatory agent. However, eﬀect of myrrh on peritoneal macrophages
and clinically relevant models of septic shock, such as cecal ligation and puncture (CLP), is not well understood. Here,
we investigated the inhibitory eﬀect and mechanism(s) of myrrh on inﬂammatory responses. Myrrh inhibited LPS-induced
productions of inﬂammatory mediators such as nitric oxide, prostaglandin E2,a n dt u m o rn e c r o s i sf a c t o r - α but not of interleukin
(IL)-1β and IL-6 in peritoneal macrophages. In addition, Myrrh inhibited LPS-induced activation of c-jun NH2-terminal kinase
(JNK) but not of extracellular signal-regulated kinase (ERK), p38, and nuclear factor-κB. Administration of Myrrh reduced
the CLP-induced mortality and bacterial counts and inhibited inﬂammatory mediators. Furthermore, administration of Myrrh
attenuated CLP-induced liver damages, which were mainly evidenced by decreased inﬁltration of leukocytes and aspartate
aminotransferase/alanine aminotransferase level. Taken together, these results provide the evidence for the anti-inﬂammatory
and antibacterial potential of Myrrh in sepsis.
1.Introduction
Inﬂammation plays key roles in many pathophysiological
conditions [1], although it acts as an adaptive host de-
fense mechanism against infection or injury. In inﬂamma-
tory processes, macrophages are important players provid-
ing immediate defense against foreign agents. Upon activa-
tion, macrophages produce inﬂammatory mediators, such
as tumor necrosis factor-α (TNF-α), interleukin (IL), leuko-
trienes, nitric oxide (NO), and prostaglandin E2 (PGE2)
[2, 3]. Excess production of these cytokines and proinﬂam-
matory mediators is involved in many inﬂammatory dis-
eases such as atherosclerosis, rheumatoid arthritis, asthma,
pulmonary ﬁbrosis, and septic shock [4]. Thus, inhibition
of inﬂammatory responses is an important target in the
treatment of inﬂammatory diseases.
3 major MAPKs have been deﬁned: extracellular signal-
regulated kinase (ERK), c-jun NH2-terminal kinase (JNK),
and p38 [5, 6]. The activation of MAPKs is known to
be required for the productions of NO and proinﬂamma-
tory cytokines in activated macrophage cells [7]. MAPKs
signaling pathways are involved in LPS-induced expres-
sion of iNOS, COX-2, and of proinﬂammatory cytokines
in activated macrophages. Therefore, anti-inﬂammatory
drug development could include, in addition to MAPKs
inhibitors, agents that block overproduction of inﬂamma-
tory mediators by inhibiting the expression of inﬂammatory
mediators and proinﬂammatory cytokines.2 Evidence-Based Complementary and Alternative Medicine
Severe sepsis has a signiﬁcant impact on public health,
with an estimated incidence of nearly 800,000 cases per
year, resulting in over 200,000 deaths at an annual cost
of over $17 billion [8]. Sepsis develops when the initial
host response fails to contain the infection, resulting in
widespread inﬂammation and multiple organ failure [9].
The treatment of sepsis, mainly targeting inﬂammatory
mediators, has only limited success [10].
Myrrh is an oleo-gum resin obtained from Commiphora
species plants (Burseraceae). Commiphora species plants are
grown as the shrub in desert regions, particularly in north
east Africa and the Middle East. The use of Myrrh for its
antiseptic properties dates back to biblical times. Apparently,
because of its antimicrobial activity, Myrrh has historically
been used, alone and in combination with other herbal
products, to treat infections and inﬂammations. Previous
phytochemical studies of Myrrh have reported the isolation
of resin components including α-, β-, and γ-commiphoric
acids, and α-a n dβ-heerabomyrrholic acids [11, 12]. Myrrh
has showed the anti-inﬂammatory eﬀects in carcinoma cells
[13, 14]. The protective eﬀects of Myrrh on gastric ulcer
was attributed to its eﬀect on mucus production and an
increase in nucleic acid and nonprotein sulfhydryl concen-
trations, which appears to be mediated through its free
radical-scavenging, thyroid-stimulating, and prostaglandin-
inducing properties [15]. Therefore, in the present study,
we investigated anti-inﬂammatory properties of Myrrh. We
evaluateditseﬀectsonLPS-inducedinﬂammatorymediators
and on the CLP model of sepsis and its possible mechanisms
underlying anti-inﬂammatory activities, including MAPKs
and NF-κB.
2.SubjectsandMethods
2.1.ChemicalsandReagents. RPMI-1640, fetalbovineserum
(FBS), penicillin, and streptomycin were obtained from
Gibco BRL (Grand Island, NY, USA). Enzyme-linked
immunosorbant assay (ELISA) antibodies for detection of
mouse IL-1β,I L - 6 ,a n dT N F - α were purchased from R&D
Systems (Minneapolis, MN, USA). LPS from Escherichia coli
011:B4 was purchased from Sigma-Aldrich Chemical (St.
Louis, MO, USA). Antibodies against total and phospho-
speciﬁc MAPKs (ERK 1/2, JNK, and p38) and phospho-
speciﬁc inhibitory kappa-B (Iκ-B)α and JNK inhibitor,
SP600125 were from Cell Signaling Technology (Beverly,
MA, USA). Iκ-Bα monoclonal antibody and peroxidase-
conjugated secondary antibody were purchased from Santa
Cruz Biotechnology, Inc. (Santa Cruz, CA, USA). Prestained
sodium dodecyl sulfate-polyacrylamide gel electrophoresis
markers were from Bio-Rad (Hercules, CA, USA). Trizol
reagent and polymerase chain reaction (PCR) reaction kits
were purchased from Invitrogen Corporation (Carlsbad,
CA, USA). iNOS, COX-2, TNF-α,I L - 1 β,I L - 6 ,a n dβ-actin
oligonucleotide primers were purchased from Genotech
(Daejeon, South Korea).
2.2. Preparation of Myrrh Water Extract. Myrrh was pur-
chased from a standard commercial source (Omni Herb,
Daegu, Korea). The herb’s identity was conﬁrmed at the
Korean drug test laboratory. Voucher specimens were depos-
ited at the College of Oriental Medicine Herbarium of
Wonkwang University. The Myrrh (100g) was prepared
by decocting the dried prescription of herbs with boiling
distilled water (1L). The decoction time was approximately
2h. The water extract was frozen at −80◦C, then freeze-dried
to be powdered (11.56g). The yield of extract was 11.56%.
The powder was extracted with distilled water and ﬁltered.
T h eﬁ l t r a t e sw e r es t o r e da t4 ◦C until use.
2.3. Peritoneal Macrophages Culture. Thioglycollate- (TG-
) elicited peritoneal macrophages were harvested 4d after
intraperitoneal injection of 3mL TG [16]. Peritoneal lavage
was performed using 8mL of RPMI supplemented with 10%
heat-inactivated FBS. After incubation for 3h, nonadherent
cells were removed and adherent cells were replaced by new
medium, then treated with LPS in the absence or presence of
Myrrh.
2.4. MTT Assay. Cell viability was assayed using a mod-
iﬁcation of a colorimetric technique based on the ability
of live cells to convert the tetrazolium compound 3-(4,5
dimethylthiazol)-2,5-diphenyl tetrazolium bromide (MTT)
into purple formazan crystals. MTT (5mg/mL) was dis-
solved in Kreb’s-Henseleit buﬀer (115mM NaCl, 3.6mM
KCl, 1.3mM KH2PO4,2 5 m MN a H C O s ,1 MC a C l 2,a n d
1M MgCl 2). Fifty μL of the mixture was added to each
well. After 30min incubation at 37◦C, the suspension was
removed and the formazan crystals formed were dissolved in
200μLo fd i m e t h y ls u l f o x i d e .A l i q u o t sf r o me a c hw e l lw e r e
seeded in wells of a 96-well plate in duplicate and assayed
at 540nm using a micro-ELISA plate reader. The number
of Myrrh-treated viable cells was expressed as a percentage
of the control (the cell without Myrrh) maintained for a
comparable time period.
2.5. Measurement of NO Concentration. Murine peritoneal
macrophages (2×105 cells/well) were pretreated with Myrrh
for 1h and then stimulated with LPS (100ng/mL) for 24h.
To measure the NO concentration 100μL aliquots were
removed from conditioned medium and incubated with an
equal volume of Griess reagent (1% sulfanilamide/0.1% N-
(1-naphtyl)-ethylenediamine dihydrochloride/2.5% H3PO4)
at room temperature for 10min. The absorbance at 540nm
was then determined.
2.6. Western Blot. Murine peritoneal macrophages (5 × 106
cells/dish) were stimulated with 100ng/mL of LPS. Whole
cell lysates were made by boiling peritoneal macrophages
in sample buﬀer (62.5mM Tris-HCl (pH 6.8), 2% sodium
dodecyl sulfate, 20% glycerol, and 10% 2-mercaptoethanol).
Proteins in the cell lysates were then separated by 10%
SDS-PAGE and transferred to a nitrocellulose membrane.
The membrane was then blocked with 5% skim milk in
PBS-Tween-20 for 2h at room temperature and incubated
with antibodies to iNOS, COX-2, phosphorylated ERK 1/2,
phosphorylated JNK, phosphorylated p38, phosphorylated
Iκ-Bα and Iκ-Bα for overnight. After washing three times,
each blot was incubated with secondary antibody for 1hEvidence-Based Complementary and Alternative Medicine 3
and the antibody-speciﬁc proteins were visualized using an
enhanced chemiluminescence detection system (Amersham,
Piscataway, NJ, USA) according to the manufacturer’s rec-
ommended protocol.
2.7. PGE2 Assay. The PGE2 level was measured by immuno-
assay kits according to the manufacture’s protocol (Stressgen
Biotechnologies, MI, USA).
2.8. ELISA. Murine peritoneal macrophages (1 × 106 cells/
well) were stimulated with 100ng/mL of LPS and/or various
concentrations of Myrrh for 24h. Culture supernatants were
collectedandstoredat −80◦Cuntiluse.Cytokinelevelsinthe
supernatants, blood, and peritoneal ﬂuid were determined
using a commercial system (R&D Systems) according to
the manufacturer’s instructions. The ELISA was devised by
coating 96-well plates with speciﬁc for TNF-α,I L - 1 β,a n dI L -
6. The coated plates were washed with PBS containing 0.05%
Tween-20. All reagents used in this assay were incubated
for overnight at 4◦C. Recombinant TNF-α,I L - 1 β,a n dI L - 6
were diluted and used as a standard. Serial dilutions starting
at 20ng/mL were used to establish the standard curve.
Assay plates were exposed sequentially to biotinylated mouse
TNF-α,I L - 1 β, and IL-6 avidin peroxidase, and a substrate
solution of 2,2 -azino-bis-[3-ethylbenzthiazoline-6-sulfonic
acid] (ABTS) containing 30% hydrogen peroxide. The plates
were read at 405nm.
2.9. RNA Quantiﬁcation. Total cellular and liver RNA was
isolated by using the Trizol (Invitrogen, Carlsbad, CA, USA)
extraction according to the manufacture’s instructions. Total
RNA (1μg) was converted to cDNA by 200 units of reverse
transcriptase and 500ng of oligo-dT primer in 50mM Tris-
HCl (pH 8.3), 75mM KCl, 3mM MgCl2,1 0m MD T T ,a n d
1mM dNTPs at 42 ◦C for 1h. The reaction was stopped
by heating at 70◦Cf o r1 5 m i na n d3 μL of the cDNA
mixture was used for enzymatic ampliﬁcation. PCR was
performedin50mMKCl,10mMTris-HCl(pH8.3),1.5mM
MgCl2, 0.2mM dNTPs, 2.5 units of Taq DNA polymerase,
and 0.1μM each of primers for iNOS, COX-2, TNF-α,
IL-1β,I L - 6 ,a n dβ-actin. Ampliﬁcations of conditions were
denaturation at 94◦C for 3min for the ﬁrst cycle and for
45s starting from the second cycle, annealing for iNOS at
55◦C for 40s, COX-2 at 65◦Cf o r4 0s ,T N F - α at 62◦Cf o r
20s, IL-1β,I L - 6 ,β-actin at 58◦C for 45s, for 35 cycles. Final
extension was performed at 72◦Cf o r7m i n .P C Rp r o d u c t s
were electrophorased on a 1.5% agarose gel and stained with
ethidium bromide. Primers used were 5 -AGC CCA ACA
ATA CAA ATG ACC CTA-3  (forward) and 5 -TTC CTG
TTG TTT CTA TTT CCT TTGT-3  (reverse) for iNOS, 5 -
CAC TCA GTT TGT TGA GTC ATTC-3  (forward) and
5 -GAT TAG TAC TGT AGG GTT AAT G-3 (reverse) for
COX-2,5 -ATGAGCACAGAAAGCATGATC-3  (forward)
and 5 -TAC AGG CTT GTC ACT CGA ATT-3  (reverse) for
TNF-α,5  -AGT ATC ACT CAT TGT GGC TG-3  (forward)
and 5 -TCA CAG AGG ATG GGC TCT TC-3  (reverse) for
IL-1β,5  -TCA CAG AGG ATG GGC TCT TC-3  (forward)
and 5 -CAT CCA GTT GCC TTC TTG GGA-3  (reverse) for
IL-6,5 -TGTGATGGTGGGAATGGGTCAG-3  (forward)
and 5 -TTT GAT GTC ACG CAC GAT TTC C-3  (reverse)
for β-actin.
2.10. Nuclear Extraction and NF-κBBindingActivity. Murine
peritoneal macrophages were plated in 100-mm dishes
(1 × 107 cells/dish). The cells were treated with Myrrh
(0.5mg/mL), stimulated with LPS for the time as indicated.
Nuclear extracts were prepared by nuclear extraction kit
from Panomics (CA, USA). The isolated cytosol was kept
at −80◦C for western blot. The nuclear extraction was used
for examining NF-κB binding activity. The NF-κB binding
activity was measured by NF-κB p65 binding activity assay
kit from Active Motif (CA, USA).
2.11. Cecal Ligation and Puncture. We performed CLP as
described previously [17]. Brieﬂy, we anesthetized the mice
andshavedtheabdominalwall.Aftermidlinelaparotomy,we
exposed the cecum, ligated below the ileocecal valve without
causing intestinal obstruction and then punctured with a
21G needle. We assessed clinical score every 24h after CLP,
We determined survival rate daily for 8d after CLP.
2.12. Bacterial Counts. We determined bacterial counts as
described previously [17]. Brieﬂy, we collected peritoneal
lavage ﬂuids using PBS and blood 6 and 24h after CLP. We
serially diluted the samples, plated them on agar dishes and
incubated the dishes for 24h at 37◦C. Bacterial counts were
determined by counting colony-forming units.
2.13. Peritoneal Leukocyte Counts. Peritoneal leukocyte
counts were measured by Diﬀ Quik staining kit according to
the manufacture’s protocol (Sysmex, Japan).
2.14. Histopathology Analysis. Liver of mice were excised at
24h after CLP. The liver samples were ﬁxed in 10% formal-
dehyde at room temperature. Then the samples were paraf-
ﬁn embedded, cut into 4μm sections, and stained with
hematoxylin-eosin.
2.15. Aspartate Aminotransferase (AST)/Alanine Aminotrans-
ferase (ALT) Analysis. The fresh serum was used for assaying
AST/ALT using biochemical kits (Span Diagnostics, Surat,
France).
2.16. Myeloperoxidase (MPO) Estimation. Neutrophil se-
questration in the liver was quantiﬁed by measuring tissue
MPO activity. Tissue samples were thawed, homogenized
in 20mM phosphate buﬀer (pH 7.4), and centrifuged
(13,000rpm, 10min, 4◦C). The pellet was resuspended in
50mM phosphate buﬀer (pH 6.0) containing 0.5% hex-
adecyltrimethylammonium bromide (Sigma-Aldrich). The
suspension was subjected to four cycles of freezing and
thawingandwasfurtherdisruptedbysonicationfor40s.The
sample was then centrifuged (13,000rpm, 5min, 4◦C), and
the supernatant was used for the MPO assay. The reaction
mixture consisted of the supernatant, 1.6mM tetramethyl-4 Evidence-Based Complementary and Alternative Medicine
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Figure 1: Eﬀects of myrrh on LPS-induced cytokine production. (a) The eﬀects of myrrh on cell viability were measured by MTT assay.
Peritoneal macrophages were incubated with or without Myrrh as indicated dose for 24h. (b) The cells were treated with Myrrh as indicated
dose,thenstimulatedwithLPS(100ng/mL)for24h.Thesupernantswereharvested,thenthelevelsofIL-1β,IL-6,andTNF-αweremeasured
by ELISA as described in Subjects and Methods. (c) The cells were pretreated with myrrh as indicated dose for 1h, then stimulated with LPS
(100ng/mL)for24h.CellsweretakenforRT-PCR.TotalRNA(1μg)waspreparedfortheRT-PCRofIL-1β,IL-6,TNF-α.TheIL-1β(126bp),
IL-6 (488bp), and TNF-α (276bp) were detected by agarose gel electrophoresis, as described in Subjects and Methods. Actin (514bp) was
used as loading control. The values are means ± SD of three independent experiments. ∗P<0.05 versus saline. +P<0.05 versus LPS.
benzidine(Sigma-Aldrich),80mMsodiumphosphatebuﬀer
(pH 5.4), and 0.3mM hydrogen peroxide. This mixture was
incubatedat37◦Cfor110sandtheabsorbancewasmeasured
at 450nm.
2.17. Statistical Analysis. The results are expressed as the
mean ± S.D. of independent experiments. Two-way ANOVA
was used to analyze the statistical signiﬁcance of the results
between or among groups, and if statistically signiﬁcant, post
hoc analysis using the Duncan method was followed as a
multiple comparison among groups. All statistical analyses
were performed using SPSS, version 10.0 statistical analysis
software. ∗P<0.05 were considered to indicate statistical
signiﬁcance.
3. Results
3.1. Eﬀects of Myrrh on LPS-Induced Production of IL-1β,
IL-6, and TNF-α. To examine the anti-inﬂammatory ef-
fectofMyrrhonperitonealmacrophages,weanalyzedproin-
ﬂammatory cytokine productions. A prerequisite to study
the biological activity of any compound or plant extract
is to ensure that they do not have a detrimental eﬀect
on cell metabolism. To determine if Myrrh extract aﬀects
cell viability, peritoneal macrophages were incubated for
24h with the extract as indicated dose, and cell viability
was evaluated by MTT assay. Myrrh extract did not aﬀect
cell death (Figure 1(a)). Thus, a concentration range of
0.1–1mg/mL was chosen for treatment in the follow-up
experiments. We examined the eﬀects of Myrrh on LPS-
inducedIL-1β,IL-6,andTNF-αproductionusingELISAand
RT-PCR. We found that the pretreatment of Myrrh extract
inhibited LPS-induced production of TNF-α but not ofIL-1β
and IL-6 (Figures 1(b) and 1(c)).
3.2. Eﬀects of Myrrh on LPS-Induced PGE2 and NO Produc-
tion. Next, we examined COX-2 protein levels and mRNA
expressions. Peritoneal macrophages were pretreated withEvidence-Based Complementary and Alternative Medicine 5
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Figure 2: Eﬀects of Myrrh on LPS-induced inﬂammatory mediators. Peritoneal macrophages were pretreated with myrrh as indicated dose
for 1h, then stimulated with LPS (100ng/mL) for 24h. (a) The eﬀects of myrrh on LPS-induced COX-2 protein and mRNA expression, (b)
PGE2 production, (c) iNOS protein and mRNA expression, and (d) NO production were measured. The cells were taken for western blot
and RT-PCR. For western blot, total cellular proteins (20μg) were resolved by SDS-PAGE, transferred to PVDF membrane, and detected
with COX-2 (70kDa) and iNOS (131kDa) antibody, as described in Subjects and Methods. Actin (42kDa) was used as loading control. A
representative western blot of three experiments is shown. For RT-PCR, Total RNA (1μg) was prepared for the RT-PCR of COX-2 and iNOS.
The COX-2 (696bp) and iNOS (734bp) were detected by agarose gel electrophoresis, as described in Subjects and Methods. Actin (514bp)
was used as loading control. The supernants were harvested, then PGE2 and NO levels were measured as described in Subjects and Methods.
The values are means ± SD of three independent experiments. ∗P<0.05 versus saline. +P<0.05 versus LPS.
the indicated concentrations of Myrrh extract for 1h and
then stimulated with 100ng/mL of LPS for 24h. Pre-
treatment of Myrrh extract inhibited LPS-induced levels of
inﬂammatory mediators such as COX-2 and PGE2 (Figures
2(a) and 2(b)). Next, we examined NO production in
peritoneal macrophages. The pretreatment of Myrrh extract
inhibited LPS-induced iNOS mRNA expressions and protein
levels in a dose-dependent manner (Figure 2(c)). As shown
in Figure 2(d), in agreement with iNOS results, pretreatment
of Myrrh extract inhibited LPS-induced NO production in a
dose-dependent manner.
3.3. Eﬀects of Myrrh on Activation of NF-κB and MAPK.
To ﬁnd out inhibitory mechanisms of Myrrh extract on
inﬂammatory mediators, we examined the NF-κBa n d
MAPKs pathway. The cells were treated with Myrrh for 1h,
and then stimulated with LPS as indicated time. As shown in
Figure 3(a), Myrrh did not inhibit the phosphorylation and6 Evidence-Based Complementary and Alternative Medicine
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Figure 3: Eﬀects of myrrh on LPS-induced NF-κB activation. (a)
Peritoneal macrophages (1 × 107/100mm dish) were treated with
myrrh (0.5mg/mL) for 1h, then stimulated with LPS as indicated
time points. The cells were harvested for isolation of cytosol and
nucleus. The nucleus fraction was performed by Nucleus extraction
kit as described in Subjects and Methods. The cytosol was used
for western blot. Total cellular proteins (20μg) were resolved by
SDS-PAGE, transferred to PVDF membrane and detected with
phosphospeﬁc Iκ-Bα (36kDa), anti-Iκ-Bα (32kDa) antibody, as
described in Subjects and Methods. Actin (42kDa) was used as
loading control. A representative western blot of three experiments
is shown. (b) The fractioned nucleus was assayed for DNA (NF-κB
p65)-binding activity. The binding activity was measured by NF-κB
p65 binding activity kit as described in Subjects and Methods. The
valuesaremeans ±SDofthreeindependentexperiments. ∗P<0.05
versus saline.
degradation of Iκ-Bα. In addition, NF-κB binding activity
was also not aﬀected by Myrrh (Figure 3(b)). LPS induced
phosphorylation of ERK 1/2, JNK, and p38. However, Myrrh
extract inhibited the phosphorylation of JNK but not of ERK
1/2 and p38 (Figure 4(a)). To examine the role of JNK on
production of NO, PGE2 and proinﬂammatory cytokines,
we used JNK speciﬁc inhibitor, SP600125. SP600125 inhib-
ited LPS-induced production of NO, PGE2,a n dT N F - α
(Figures 4(b), 4(c), and 4(d)).
3.4. Eﬀects of Myrrh on CLP-Induced Sepsis. To examine the
eﬀect of Myrrh on CLP-induced sepsis, we administrated
saline or Myrrh (0.1g/kg or 0.2g/kg) intraperitoneally
1h before CLP. In the sepsis experiment (using 21-gauge
needles),byday8afterCLP,allofthesalinetreatedmicewere
dead (0 of 20 mice), whereas Myrrh (0.2g/kg) treated group
s u r v i v e db y6 0 %( 1 2o f2 0m i c e )( Figure 5(a)). Mice were
sacriﬁced at 6h or 24h after CLP; the peritoneal cavity was
lavaged and the numbers of inﬂammatory cells were quanti-
ﬁed. The treatment of Myrrh resulted in reduced numbers of
neutrophils and macrophages (Figure 5(b)). We investigated
whethertheincreasedsurvivalofmicewasrelatedtoenhance
bacterial clearance. To determine the impact of the recruited
phagocytes on the numbers of peritoneal and blood bacteria,
serial dilutions of peritoneal lavage ﬂuid and blood were
cultured on blood agar plates. The bacterial load in blood
and peritoneal cavity was determined by CFU count at 24h
after CLP. As shown in Figure 5(c), treatment of mice with
Myrrhresultedinincreaseofbacterialclearanceinbloodand
peritoneal ﬂuids. In our mouse model, cytokines in serum
a n dp e r i t o n e a ll a v a g eﬂ u i dw e r ea l s or e d u c e da t6ha f t e rC L P
in mice treated with Myrrh (Figures 5(d) and 5(e)).
3.5. Eﬀe c t so fM y r r ho nC L P - I n d u c e dL i v e rI n j u r y .Next, we
examined the eﬀect of Myrrh on liver injury of septic mice.
Myrrh treatment remarkably inhibited the inﬂammatory
cells and tissue degeneration in liver tissues (Figure 6(a)).
To ascertain the eﬀect of Myrrh on neutrophil inﬁltration
into liver tissues, we examined the MPO activity in tissues of
septic mice. Consistent with ﬁndings from histopathological
examination, MPO activity in liver tissues of septic mice was
increased. However, Myrrh treatment resulted in signiﬁcant
reduction of MPO activity live tissues of mice (Figure 6(b)).
To further determine the hepatoprotective eﬀect of Myrrh,
we examined serum AST and ALT activities in septic mice.
As shown in Figure 6(c), CLP resulted in signiﬁcant increase
of AST and ALT activities compared with sham operation.
However, treatment of mice with Myrrh reduced AST and
ALT activities. Next, we examined the eﬀect of Myrrh on
cytokine expressions in liver from CLP-induced septic mice.
Myrrh treatment reduced the expressions of IL-1β,I L - 6 ,a n d
TNF-α mRNA in liver (Figure 6(d)).
4. Discussion
Myrrh is the dried oleo-gum resin of a number of Com-
miphora species, and it has been known to contain resin,
essential oil, and gum [18]. Many studies investigated the
pharmacological eﬀects of Myrrh [19–21]. However, the
eﬀects and the mechanisms underlying the protective eﬀects
against sepsis and anti-inﬂammatory activities of Myrrh are
poorly deﬁned. In this study, pretreatment of myrrh inhib-
ited LPS-induced production of proinﬂammatory cytokines,
NO, and PGE2 in peritoneal macrophages (Figures 3 and 4).
We also found that myrrh reduced CLP-induced mortality
and inhibited CLP-induced production of IL-1β,I L - 6 ,a n d
TNF-α in serum and liver (Figures 5 and 6). These results
suggest that myrrh may have anti-inﬂammatory properties.Evidence-Based Complementary and Alternative Medicine 7
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LPSinducesproinﬂammatorycytokineproductionssuch
as TNF-α,I L - 1 β, and IL-6. Among these, TNF-α is one of the
most important cytokines and is required for the synergistic
induction of NOS in LPS-stimulated macrophages. TNF-
α elicits a number of physiological eﬀect, such as septic
shock, inﬂammation, cachexia, and cytotoxicity [22]. In the
present study, our results demonstrated that Myrrh (0.1 ∼
1mg/mL) inhibits LPS-induced production of TNF-α but
not of IL-1β and IL-6 (Figure 1). We further investigated
the eﬀect of myrrh (0.1 ∼ 1mg/mL) on NO and PGE 2
production. NO, generated from L-arginine by iNOS, is an
important regulatory molecule in a range of physiological8 Evidence-Based Complementary and Alternative Medicine
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and pathological processes [23]. iNOS produce micromolar
range of NO that is responsible for a number of pathological
conditions including various inﬂammatory diseases. Our
results demonstrated that Myrrh inhibited the production
of NO through suppression of iNOS expression (Figures
2(c) and 2(d)). Another key inﬂammatory mediator is PGE2,
which is produced by COX [24]. PGE2 is signiﬁcantly
elevated in the plasma of septic or injured patients and
is thought to be a component of the resultant immune
suppressionassociatedwithaugmentedratesofinfectionand
mortality[25].COXenzymehastwoisoformsofconstitutive
form (COX-1) and inducible form (COX-2) [24]. The
present study demonstrated that myrrh (0.1 ∼ 1mg/mL)
inhibited the production of PGE2 through the suppression
of COX-2 expression (Figures 2(b) and 2(c)).
To further characterize the inhibitory eﬀect of Myrrh
(0.5mg/mL) on inﬂammatory response, we examined the
eﬀects of myrrh on the activation of transcription factor
NF-κB and MAPKs, which regulate the expression of many
immune and inﬂammatory genes. NF-κB is known to play
a critical role in the regulation of cell survival genes and
to coordinate the expressions of proinﬂammatory enzymes
and cytokines, such as iNOS, COX-2, TNF-α, and IL-6 [26].
The activity of NF-κB is regulated by an inhibitory protein,
Iκ-Bα. When cells are activated, the inhibitory proteins
undergo phosphorylation, which subsequently leads to the
degradation of Iκ-Bα. The loss of Iκ-Bα results in the release
of free NF-κB units that translocate from the cytoplasm to
the nucleus, where they may trigger the transcription of
speciﬁc target genes. In the present study, we found that
Myrrh did not inhibit LPS-induced phosphorylation and
degradation of Iκ-Bα and NF-κB activity (Figures 4(a) and
4(b)). Our results suggest that inhibitory eﬀects of myrrh on
the production of NO, PGE2,a n dT N F - α do not involve in
NF-κB signaling.
MAPKs (ERK, JNK, p38) react to diverse extracellular
stimuli and regulate various cellular activities including
signal transduction and expression of proinﬂammatory10 Evidence-Based Complementary and Alternative Medicine
mediators. In this study, we found that Myrrh signiﬁcantly
inhibited activation of JNK but not of p38 and ERK
(Figure 5(a)). Using speciﬁc JNK inhibitor, SP600125, we
demonstrated that LPS-activated macrophages, initiated sys-
temic response which are characterized by the production of
NO, PGE2,a n dT N F - α through JNK activation. Our results
suggested that myrrh might inhibit LPS-induced production
of NO, PGE2,a n dT N F - α through the inhibition of the JNK
pathway (Figures 5(b), 5(c), and 5(d)).
In the CLP model, bacteria spreading from infection sites
and entering the bloodstream are rapidly trapped in the
manyorgans such as liver, lung, kidney, and spleen, bound to
thesurfaceofspeciﬁctargetcellsandmacrophagesinthetar-
get organ and subsequently killed by inﬁltrated neutrophils
[27, 28]. The organs are impaired in mice with lethal sepsis
induced by CLP and also in humans with sepsis, and this
impairment is associated with ineﬀective bacterial clearance,
leading to bacterial dissemination and high mortality rates
[29]. Several reports have demonstrated that inﬂammatory
cytokines can serve as both makers and mediators of the
severity of sepsis and that elevated levels of these cytokines
predict mortality following CLP [29–31]. In this experiment,
the administration of myrrh (0.1 or 0.2g/kg) led to a marked
increase in survival and an increased bacterial clearance
(Figure 5). In contrast with in vitro results, myrrh treatment
reduced levels of proinﬂammatory cytokines such as IL-1β,
IL-6, and TNF-α in serum and peritoneal ﬂuids. Therefore,
it is likely that Myrrh exerted an anti-inﬂammatory eﬀect
in vivo by increasing bacterial clearance and inhibiting
proinﬂammatory cytokines production such as IL-1β,I L - 6 ,
and TNF-α.
The liver plays a central role in the metabolism and
supportsthedefensesystemsofthebody[32].Animpending
liver organ dysfunction is therefore an ominous sign in
critically ill patients, and the development of hepatic failure
during sepsis is associated mortality [33]. Because organ
dysfunction is considered to be the end point of damage
caused by the excessive inﬂammatory response of sepsis,
we therefore examined the level of AST and ALT, MPO
activity, cytokine production, and histology during sepsis.
In the present study, we demonstrated that treatment of
mice with myrrh reduced plasma AST and ALT level and
MPO activity in liver from CLP-induced mice (Figure 6),
indicatingthatmyrrhreducedhepaticinjuryinCLP-induced
mice. To explore the mechanisms of the development of
sepsis-induced hepatic injury, we investigated whether an
excessive hepatic inﬂammatory response developed sepsis-
induced hepatic injury, as evidenced by the fact that a
number of inﬂammatory mediators play pivotal roles in the
development of CLP-induced hepatic injury [34, 35]. TNF-
α and IL-1β are the most powerful pathological cytokines
causing cell degeneration, apoptosis, and necrosis, and
leading to multiple organ dysfunction [36]. In addition,
TNF-α and IL-1β can also boost the other inﬂammatory
mediators [35]. In our study, treatment of myrrh reduced
expression of IL-1β,I L - 6 ,a n dT N F - α in serum and liver
during CLP-induced sepsis (Figures 5 and 6). Histopatho-
logical examination, AST/ALT levels, and MPO activity also
indicated that myrrh alleviated cellular damage in live tissue.
These results supported that the protective eﬀect of myrrh
on liver in septic mice might be achieved by inhibition of
proinﬂammatory cytokine overproduction.
In conclusion, we demonstrated that myrrh treatment
could show anti-inﬂammatory eﬀects on LPS-stimulated
macrophages and antimicrobial sepsis on CLP model. The
pretreatment of myrrh inhibited NO, PGE2,a n dT N F - α
productionthroughinhibitionofJNKpathway.Theseresults
could give the conclusion that myrrh has a potential in
deactivating inﬂammatory cells such as macrophages and
might be beneﬁcial in inﬂammatory diseases such as sepsis.
5. Authors’ Contribution
Both M-S Kim and G-S Bae equally contributed to this work.
Acknowledgment
This work has been ﬁnancially supported by Korea Research
Council for industrial Science & Technology through the
Project of Convergence Manufacturing Technology Devel-
opment of Bio-Medical Applicable Systems for Geriatric
Disease (B551179-09-02-00).
References
[ 1 ] H .J .L e e ,H .J .L i m ,D .Y .L e ee ta l . ,“ C a r a b r o ls u p p r e s s e sL P S -
inducednitricoxidesynthaseexpressionbyinactivationofp38
and JNK via inhibition of I-κBα degradation in RAW 264.7
cells,” Biochemical and Biophysical Research Communications,
vol. 391, no. 3, pp. 1400–1404, 2010.
[2] M.GuhaandN.Mackman,“LPSinductionofgeneexpression
in human monocytes,” Cellular Signalling, vol. 13, no. 2, pp.
85–94, 2001.
[3] P. Kubes and D. M. McCaﬀerty, “Nitric oxide and intestinal
inﬂammation,” American Journal of Medicine, vol. 109, no. 2,
pp. 150–158, 2000.
[4] W. W. Lin and M. Karin, “A cytokine-mediated link between
innate immunity, inﬂammation, and cancer,” Journal of Clini-
cal Investigation, vol. 117, no. 5, pp. 1175–1183, 2007.
[ 5 ]E .D .C h a na n dD .W .H .R i c h e s ,“ I F N - γ + LPS induction of
iNOS is modulated by ERK, JNK/SAPK, and p38mapk in a
mouse macrophage cell line,” American Journal of Physiology,
vol. 280, no. 3, pp. C441–C450, 2001.
[6] M. H. Cobb and E. J. Goldsmith, “Dimerization in MAP-
kinase signaling,” Trends in Biochemical Sciences, vol. 25, no.
1, pp. 7–9, 2000.
[7] P. Celec, “Nuclear factor kappa B—molecular biomedicine:
the next generation,” Biomedicine and Pharmacotherapy, vol.
58, no. 6-7, pp. 365–371, 2004.
[8] D. C. Angus, W. T. Linde-Zwirble, J. Lidicker, G. Clermont,
J. Carcillo, and M. R. Pinsky, “Epidemiology of severe sepsis
in the United States: analysis of incidence, outcome, and
associated costs of care,” Critical Care Medicine, vol. 29, no.
7, pp. 1303–1310, 2001.
[9] R. S. Hotchkiss and I. E. Karl, “The pathophysiology and
treatmentofsepsis,”NewEnglandJournalofMedicine,vol.348,
no. 2, pp. 138–150, 2003.
[10] N. C. Riedemann, R. F. Guo, and P. A. Ward, “Novel strategies
for the treatment of sepsis,” Nature Medicine, vol. 9, no. 5, pp.
517–524, 2003.Evidence-Based Complementary and Alternative Medicine 11
[11] A. M. Tonkal and T. A. Morsy, “An update review on
Commiphora molmol and related species,” J o u r n a lo ft h e
Egyptian Society of Parasitology, vol. 38, no. 3, pp. 763–796,
2008.
[12] L. O. Hanus, T. Rezanka, V. M. Dembitsky, and A. Moussaieﬀ,
“Myrrh—Commiphora chemistry,” Biomedical Papers of The
Medical Faculty of the University Palacky Olomouc Czechoslo-
vakia, vol. 149, no. 1, pp. 3–27, 2005.
[13] M. Tariq, A. M. Ageel, and M. A. Al-Yahya, “Anti-
inﬂammatory activity of Commiphora molmol,” Agents and
Actions, vol. 17, no. 3-4, pp. 381–382, 1986.
[ 1 4 ]S .Q u r e s h i ,M .M .A l - H a r b i ,M .M .A h m e d ,M .R a z a ,A .
B. Giangreco, and A. H. Shah, “Evaluation of the genotoxic,
cytotoxic, and antitumor properties of Commiphora molmol
using normal and Ehrlich ascites carcinoma cell-bearing Swiss
albinomice,”CancerChemotherapyandPharmacology,vol.33,
no. 2, pp. 130–138, 1993.
[15] K. Bone, “A clinical guide to blending herbs,” in Herbal
Formulatons for the Individual Patient, pp. 335–337, Churchill
Livingstone, 1st edition, 2003.
[16] S. Narumi and T. A. Hamilton, “Dexamethasone selectively
regulates LPS-inducible gene expression in murine peritoneal
macrophages,” Immunopharmacology, vol. 19, no. 2, pp. 93–
101, 1990.
[17] J. C. Alves-Filho, A. De Freitas, M. Russo, and F. Q. Cunha,
“Toll-like receptor 4 signaling leads to neutrophil migration
impairment in polymicrobial sepsis,” Critical Care Medicine,
vol. 34, no. 2, pp. 461–470, 2006.
[18] A. Chevallier, The Encyclopedia of Medicinal Plants, Dorling
Kindersley Inc., London, UK, 1986.
[19] M. M. al-Harbi, S. Qureshi, M. M. Ahmed, S. Rafatullah,
and A. H. Shah, “Eﬀect of Commiphora molmol (oleo-gum-
resin) on the cytological and biochemical changes induced
by cyclophosphamide in mice,” American Journal of Chinese
Medicine, vol. 22, no. 1, pp. 77–82, 1994.
[20] A. Massoud, S. El Sisi, O. Salama, and A. Massoud, “Prelimi-
nary study of therapeutic eﬃcacy of a new fasciolicidal drug
derived from Commiphora molmol (MYRRh),” American
Journal of Tropical Medicine and Hygiene,v o l .6 5 ,n o .2 ,p p .
96–99, 2001.
[21] Z. Sheir, A. A. Nasr, A. Massoud et al., “A safe, eﬀective, herbal
antischistosomal therapy derived from myrrh,” American
Journal of Tropical Medicine and Hygiene,v o l .6 5 ,n o .6 ,p p .
700–704, 2001.
[22] N. Parameswaran and S. Patial, “Tumor necrosis factor-α
signaling in macrophages,” Critical Reviews in Eukaryotic Gene
Expression, vol. 20, no. 2, pp. 87–103, 2010.
[23] C. Nathan and Q. W. Xie, “Regulation of biosynthesis of nitric
oxide,” Journal of Biological Chemistry, vol. 269, no. 19, pp.
13725–13728, 1994.
[24] W. L. Smith, L. J. Marnett, and D. L. DeWitt, “Prostaglandin
and thromboxane biosynthesis,” Pharmacology and Therapeu-
tics, vol. 49, no. 3, pp. 153–179, 1991.
[25] E. L. Hahn, K. D. Clancy, H. H. Tai, J. D. Ricken, L. K. He,
and R. L. Gamelli, “Prostaglandin E2 alterations during sepsis
are partially mediated by endotoxin-lnduced inhibition of
prostaglandin 15-hydroxydehydrogenase,” Journal of Trauma,
vol. 44, no. 5, pp. 777–782, 1998.
[26] H.J .P ark,H.J .Lee,M.S.Choietal.,“JNKpath wa yisin v ol v ed
in the inhibition of inﬂammatory target gene expression and
NF-kappaB activation by melittin,” Journal of Inﬂammation,
vol. 5, article 7, 2008.
[27] S. H. Gregory, L. K. Barczynski, and E. J. Wing, “Eﬀector
function of hepatocytes and Kupﬀer cells in the resolution of
systemicbacterialinfections,”J o urnalo fL euk ocyt eBio logy,vol.
51, no. 4, pp. 421–424, 1992.
[28] K. A. Owen, F. J. Pixley, K. S. Thomas et al., “Regulation of
lamellipodial persistence, adhesion turnover, and motility in
macrophages by focal adhesion kinase,” Journal of Cell Biology,
vol. 179, no. 6, pp. 1275–1287, 2007.
[29] S. E. Moreno, J. C. Alves-Filho, F. Rios-Santos et al., “Signaling
viaplatelet-activatingfactorreceptorsaccountsfortheimpair-
mentofneutrophilmigrationinpolymicrobialsepsis,”Journal
of Immunology, vol. 177, no. 2, pp. 1264–1271, 2006.
[30] D. G. Remick, G. Bolgos, S. Copeland, and J. Siddiqui, “Role
of interleukin-6 in mortality from and physiologic response to
sepsis,” Infection and Immunity, vol. 73, no. 5, pp. 2751–2757,
2005.
[31] E. R. Sherwood, V. T. Enoh, E. D. Murphey, and C. Y. Lin,
“Mice depleted of CD8+ T and NK cells are resistant to
injury caused by cecal ligation and puncture,” Laboratory
Investigation, vol. 84, no. 12, pp. 1655–1665, 2004.
[32] F. Hawker, “Liver dysfunction in critical illness,” Anaesthesia
and Intensive Care, vol. 19, no. 2, pp. 165–181, 1991.
[ 3 3 ]B .G .H a r b r e c h t ,B .W u ,S .C .W a t k i n s ,T .R .B i l l i a r ,a n dA .B .
Peitzman, “Inhibition of nitric oxide synthesis during severe
shock but not after resuscitation increases hepatic injury and
neutrophil accumulation in hemorrhaged rats,” Shock, vol. 8,
no. 6, pp. 415–421, 1997.
[34] F. A. Bozza, J. I. Salluh, A. M. Japiassu et al., “Cytokine proﬁles
as markers of disease severity in sepsis: a multiplex analysis,”
Critical Care, vol. 11, no. 2, article R49, 2007.
[35] C.A.Dinarello,“Cytokinesasmediatorsinthepathogenesisof
septic shock,” Current Topics in Microbiology and Immunology,
vol. 216, pp. 133–165, 1996.
[36] S. Ghosh, R. D. Latimer, B. M. Gray, R. J. Harwood, and
A. Oduro, “Endotoxin-induced organ injury,” Critical Care
Medicine, vol. 21, no. 2, pp. S19–S24, 1993.